Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2014 Q2- Text added to 2014 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
New words:
Biosyn, composition, Confidential, defend, doubt, Education, entity, EU, expiry, extend, Feedback, felt, footnote, formally, global, implementing, insight, ipilumumab, Japan, matter, mek, momentum, NCI, offset, originally, osteosarcoma, parallel, pending, post, promulgated, requested, Rule, Scientific, sequentially, size, spoken, sunitinib, traditional, unchanged, undergoing, underway, vigorously
Removed:
GTR, half, transplant
Valuein 2014 Q2 filing- Value in 2014 Q3 filing
Original filings
Filing view